Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Use the pullback to buy pullback in this MedTech stock: JPMorgan
August 12, 2024 4:00 PM EDTJPMorgan analysts urged investors to capitalize on the recent pullback in one medtech company's shares.
The firm said in a note to clients Monday that Insulet's (NASDAQ: PODD) strong fundamentals and positive outlook mean they are buyers.
The analysts express frustration over the stock's decline following earnings last week, emphasizing that the drop is not reflective of the company's... More
Insulet Corporation (PODD) PT Lowered to $250 at BTIG
August 9, 2024 4:58 AM EDTBTIG analyst Marie Thibault lowered the price target on Insulet Corporation (NASDAQ: PODD) to $250.00 (from $270.00) while maintaining a Buy rating.
The analyst comments "Following its preannouncement in late July, Insulet reported Q2 revenue of $488.5M (+23% y/y rep and cc), a ~$27M beat on consensus at the time of the preannouncement. The beat came from all business segments and was attributed to strong O5 demand that drove sequential increases in new customer starts both in the... More
